# Toxic Epidermal Necrolysis Caused by Eribulin

## TL;DR

A patient with angiosarcoma developed a rare skin condition called toxic epidermal necrolysis after receiving the chemotherapy drug eribulin.

## Contribution

This paper reports a rare adverse reaction to eribulin, highlighting its potential to cause toxic epidermal necrolysis.

## Key findings

- A patient developed severe skin and mucosal lesions after the third dose of eribulin.
- Steroid therapy improved the condition, but eruptions recurred with further eribulin treatment.
- The case suggests a need to study eribulin's immunological effects and its relation to severe drug eruptions.

## Abstract

Eribulin, a chemotherapy drug classified as a microtubule inhibitor, is known to target cell microtubule structures, impeding cancer cell growth and spread. This paper discusses a rare case of toxic epidermal necrolysis (TEN) induced by eribulin in a patient with angiosarcoma, marking it as an uncommon adverse reaction. This patient developed severe mucosal and skin lesions after the third dose of eribulin. Laboratory tests and a skin biopsy confirmed the diagnosis of TEN. The patient responded well to steroid therapy, although skin eruptions reoccurred with further eribulin treatment. This case highlights the need for further study on the immunological effects of eribulin, especially concerning severe drug eruptions potentially related to its impact on microtubule dynamics and immune cell functions.